The purpose of this study is to determine the efficacy of Droxidopa for the treatment of fatigue in patients with Parkinsonism by the Visual Analog Fatigue Scale (VAFS). This is a randomized, placebo-controlled, double-blind clinical trial for 3 months where half the subjects will receive placebo and the other half will receive Droxidopa. Following this will be a wash-out period of 7 days and then all subjects will receive Droxidopa for 3 months during the open-label phase.

Start Date01 Dec 2021

Sponsor / Collaborator

Loma Linda University

[+1]

NCT04977388

/ RecruitingPhase 1/2IIT

Phase I/II Study of NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Adults With Occipital Horn Syndrome: Double-blind Placebo-controlled Randomized Crossover Clinical Trial

The purpose of this study is to evaluate whether Northera (Droxidopa) is safe and effective in young adults with Menkes disease who survived the most severe complications of their illness or adults with occipital horn syndrome (OHS), who have trouble with intermittent low blood pressure and other symptoms of dysautonomia. The outcomes and information from this study may help adult survivors of Menkes disease and individuals with OHS lead more normal day-to-day lives.

Start Date12 Jul 2021

Sponsor / Collaborator

Nationwide Children's Hospital

NCT04510922

/ CompletedPhase 4IIT

Technology-Based Objective Measures for Gait and Postural Assessment in Parkinson Disease Patients With Orthostatic Hypotension: Feasibility and Effect-Size Finding Study

Orthostatic hypotension (OH), which consists in a significant reduction in blood pressure levels upon standing from a seated position, may affect approximately one in three patients with Parkinson's disease (PD). It usually presents as dizziness, lightheadedness, feeling faint, or feeling like you might black out while standing. This can significantly impact the quality of life (QoL) of PD patients, resulting in difficulties with balance, walking, and increased risk of falls. The main aim of this study is to evaluate whether the use of technological devices (a computerized system for analyzing abnormalities in walking in clinical settings and a wearable sensor to detect changes in postural unsteadiness in the home environment) may improve the detection of complications and the response to medical therapies for OH in patients with PD.

Start Date11 Feb 2019

Sponsor / Collaborator

University of Cincinnati (Ohio)

[+1]

100 Clinical Results associated with Droxidopa

100 Translational Medicine associated with Droxidopa

100 Patents (Medical) associated with Droxidopa

1,174

Literatures (Medical) associated with Droxidopa

01 Apr 2025·Toxicology in Vitro

TPD-seq: A high throughput RNA-seq method to derive transcriptomic points of departure from cell lines

Article

Author: Xia, Jianguo ; Rulli, Samuel J ; Mittal, Krittika ; Basu, Niladri ; Zhou, Guangyan ; Xu, Ke

There is growing scientific and regulatory interest in transcriptomic points of departure (tPOD) values from high-throughput in vitro experiments. To further help democratize tPOD research, here we outline 'TPD-seq' which links microplate-based exposure methods involving cell lines for human (Caco-2, Hep G2) and environmental (rainbow trout RTgill-W1) health, with a commercially available RNA-seq kit, with a cloud-based bioinformatics tool (ExpressAnalyst.ca). We applied the TPD-seq workflow to derive tPODs for solvents (dimethyl sulfoxide, DMSO; methanol) and positive controls (3,4-dichloroaniline, DCA; hydrogen peroxide, H₂O₂) commonly used in toxicity testing. The majority of reads mapped to protein coding genes (∼9 k for fish cells; ∼6 k for human cells), and about 50 % of differentially expressed genes were curve-fitted from which 90 % yielded gene benchmark doses. The most robust transcriptomic responses were caused by DMSO exposure, and tPOD values were 31-155 mM across the cell lines. OECD test guideline 249 (RTgill-W1 cells) recommends the use of DCA and here we calculated a tPOD of ∼5 to 76 μM. Finally, exposure of the two human cell lines to H₂O₂ resulted in tPOD values that ranged from 0.7 to 1.1 mM in Caco-2 cells and 5-30 μM in Hep G2 cells. The methods outlined here are designed to be performed in laboratories with basic molecular and cell culture facilities, and the performance and scalability of the TPD-seq workflow can be determined with additional case studies.

01 Feb 2025·Biotechnology Letters

A recombinant L-threonine aldolase with high catalytic efficiency for the asymmetric synthesis of L-threo-phenylserine and L-threo-4-fluorophenylserine

Article

Author: Lei, Bijing ; Guo, Jian ; Zhang, Zhi ; Wang, Bochu ; Qi, Na ; Ma, Jinsong ; Pan, Yinping ; Jiang, Wan ; Wang, Caiyun

OBJECTIVESTo develop robust variants of L-threonine aldolases (L-TAs), potent catalysts for synthesizing asymmetric β-hydroxy-α-amino acids, it is necessary to identify critical residues beyond the known active site residues.RESULTSThrough virtual screening, a neglected residue Asn305, was identified as critical for catalytic efficiency. Subsequent site-saturation mutagenesis led to a potent variant N305R which exhibited excellent conversions of 88%_conv (87%_de) and 80%_conv (94%_de) for the synthesis of L-threo-phenylserine and L-threo-4-fluorophenylserine respectively. This variant not only outperformed the template enzyme, but also represented a promising L-TA for synthesizing the two β-hydroxy-α-amino acids. It was suggested that Arg305 of the variant N305R generated strong cation-arene interaction and electrostatic force with the intermediates, leading to strengthened binding, enhanced L-threo favored orientation and wider entrance.CONCLUSIONSOur work not only provided an excellent variant N305R, but also suggested the crucial function of a neglected residue Asn305, which offered valuable experiences for other L-TA studies.

01 Jan 2025·BioFactors

Catechol‐induced covalent modifications modulate the aggregation tendency of α‐synuclein: An in‐solution and in‐silico study

Article

Author: Rizzotto, Elena ; Gregoris, Francesco ; Inciardi, Ilenia ; Polverino de Laureto, Patrizia ; Minervini, Giovanni ; Sosic, Alice ; Fongaro, Benedetta

AbstractParkinson's disease (PD) stands as a challenging neurodegenerative condition characterized by the emergence of Lewy Bodies (LBs), intracellular inclusions within dopaminergic neurons. These LBs harbor various proteins, prominently including α‐Synuclein (Syn) aggregates, implicated in disease pathology. A promising avenue in PD treatment involves targeting Syn aggregation. Recent findings from our research have shown that 3,4‐dihydroxyphenylacetic acid (DOPAC) and 3,4‐dihydroxyphenylethanol (DOPET) possess the ability to impede the formation of Syn fibrils by disrupting the aggregation process. Notably, these compounds primarily engage in noncovalent interactions with the protein, leading to the formation of off‐pathway oligomers that deter fibril growth. Through proteolysis studies and mass spectrometry (MS) analysis, we have identified potential covalent modifications of Syn in the presence of DOPAC, although the exact site remains elusive. Employing molecular dynamics simulations, we delved into how DOPAC‐induced covalent alterations might affect the mechanism of Syn aggregation. Our findings indicate that the addition of a covalent adduct on certain residues enhances fibril flexibility without compromising its secondary structure stability. Furthermore, in the monomeric state, the modified residue fosters novel bonding interactions, thereby influencing long‐range interactions between the N‐ and C‐termini of the protein.

News (Medical) associated with Droxidopa

04 Mar 2024

·www.fiercehealthcare.com

Mark Cuban says Cost Plus Drugs targeting generic meds in short supply as it opens manufacturing facility

"We're about to open up our manufacturing plant this week, where we will be releasing sterile injectables for generics that are in short supply. We're going to start shipping sterile injectables and pediatric cancer drugs in about two months," Mark Cuban said. Mark Cuban Cost Plus Drug Company will begin manufacturing its own generic medications this week, starting with sterile injectables, founder and CEO Alex Oshmyansky, M.D., Ph.D., said Monday during a White House roundtable on lowering healthcare costs. The company, which launched just two years ago, will first manufacture commercial batches of epinephrine and norepinephrine for patients in the intensive care unit, Oshmyansky said. "And we, shortly after that, will be making pediatric chemotherapy, limited only by our capacity to make these products," he said. Cost Plus Drugs built a 22,000-square-foot, $11 million fill-and-finish facility in Dallas. The manufacturing facility will help address drug shortages, Oshmyanksy said. "Cost Plus Drugs is proudly bringing pharmaceutical manufacturing back to the U.S. with advanced robotic and AI computer vision technology that allows us to pivot from making one drug type to another very rapidly, in principle within four hours, that way whatever product is in shortage we can start making that product," he said. Oshmyansky, a practicing radiologist, noted that the current pharmaceutical supply chain for generic drugs is an "extremely brittle supply chain." "Only a few companies make a given drug, and they are prone to either being shut down by the FDA for unsafe practices or having their manufacturing lines physically break. The drive to lower costs also pushes drug manufacturing to China," he said. According to Oshmyansky, currently, a single vial of Penicillin G benzathine costs $600. "Penicillin-based antibiotics are required to be made in dedicated plants by the FDA, which makes it more difficult to set up alternative manufacturing in times of shortage. We at Cost Plus are aiming to work with the FDA to import Penicillin G benzathine at a price of about $3 a vial," he said. "Bypassing [pharmacy benefit managers (PBMS)] and source programs allows us to directly sell our products in times of need without being blocked by middlemen. We are pledging to be transparent in our pricing, publishing our true manufacturing cost of operating and adding a flat markup. That way we are profitable and sustainable but never extortionate," he said, adding, "No parent should be told the chemotherapy their child needs is not available. Nobody should not get the lifesaving ICU medications they need or have to postpone their surgery because the common cheap medications are just not available in united in the United States in the year 2024. These shortages are driven by the PBMs and the wholesalers and our dysfunctional model of drug distribution." Both Oshmyansky and Cuban, who initially joined the company as an investor, attended the White House roundtable on Monday. The billionaire entrepreneur and "Shark Tank" star told CNBC reporter Morgan Brennan during an interview Monday that the company's biggest challenge was keeping up with volume. "We have got millions of scrips that we have delivered, probably a couple million patients now. I mean, our numbers, we're setting records almost every single week," he said. Cost Plus Drugs currently offers about 2,500 generic medications, he noted. "The goal is to get every single drug we're legally allowed to sell. We have probably 10 different brand manufacturers that we're working with, but it's hard to add the brands because those big three PBMs are telling the brands, don't work with CostPlusDrugs.com. So that's our biggest challenge." Cost Plus Drug Company works directly with drug manufacturers to bypass middlemen and lower prices. For consumers, the price of each drug includes a 15% markup as a profit margin, a $3 pharmacy handling fee and a $5 shipping fee. Cost Plus also transparently displays what it pays for its medicines. "We're about to open up our manufacturing plant this week, where we will be releasing sterile injectables for generics that are in short supply. We're going to start shipping sterile injectables and pediatric cancer drugs in about two months," he said. Standing up the production line was a hefty investment, Cuban noted, but has been part of Cost Plus Drugs' vision to address drug shortages. "We don't have unlimited capacity, so once we can get this up and running, then we will look at ways that we can expand it. If we do this right, over the next five years, there will no longer be any more shortages in sterile injectables," he said. When asked about Cost Plus Drugs' financial operations, Cuban said the company is "not making money yet." "But that's OK. We're changing an industry, we're saving patients. I can give you example after example. A drug like Imatinib, where you might have to walk into a CVS and they will charge you $2,000 or $2,500, and, depending on the strength, you can get for $21 from Cost Plus Drugs. A drug like Droxidopa, same type of story, $10,000 for three months down to $30 a month from CostPlusDrugs.com. So I may not be making money yet. I will be. This will be self-sustaining, but the impact we're having is just incredible," Cuban said. Cuban had harsh words for the three dominant PBMs, pointing the finger at their business practices and lack of transparency for driving up drug prices. "The dominant three PBMs put stock price over health," he told the White House roundtable panel. The three biggest players in the PBM market are CVS Health's Caremark, Cigna's Evernoth/Express Scripts and UnitedHealth's OptumRx. "The craziest part is, and the message really that I wanted to get across, these big three pharmacy benefit managers, there's nothing unique about them. There is nothing that they do that so many of the independent and small transaction-based, rebate-free PBMs that couldn't do the same thing," he said during the CNBC interview. In just two years, Mark Cuban Cost Plus Drugs has become a major disruptor in generic drug pricing and has built up notable partnerships. The company now works with at least four PBMs, including Rightway, EmsanaRx, RxPreferred Benefits and PCA Rx. RELATED Fierce 50: Health Equity honorees It made waves when it inked a partnership with Coherus BioSciences to sell a biosimilar version of AbbVie’s blockbuster rheumatoid arthritis drug Humira. Cost Plus also is poised to shake up the drug benefits market. In August, Blue Shield of California, one of the state’s largest health insurers, announced it would drop CVS’ Caremark as its main PBM in favor of a new model for drug benefits. The insurer plans to partner with Cost Plus Drug Company along with Amazon Pharmacy, Abarca and Prime Therapeutics. It marked the second insurer to sign with Cost Plus, following Harrisburg, Pennsylvania-based Capital Blue last fall. Bayer also is working with the online pharmacy to provide access to Yaz birth control pills and Climara, a hormone patch for menopause. Cuban sold his majority stake in the Dallas Mavericks NBA team, and this is reportedly his last season on "Shark Tank." Asked during the CNBC interview what's next for him, Cuban replied, "Healthcare, healthcare, healthcare. It's the only company I've ever put my name on."

22 Feb 2024

·www.sciencedaily.com

Uncovering anxiety: Scientists identify causative pathway and potential cures

Quick-acting targeted therapies with minimal side effects are an urgent need for the treatment of anxiety-related disorders. While delta opioid receptor (DOP) agonists have shown 'anxiolytic' or anxiety-reducing effects, their mechanism of action is not well-understood. A new study highlights the role of specific neuronal circuits in the brain involved in the development of anxiety, and distinct mechanisms of action of the therapeutic DOP agonist -- KNT-127. Anxiety-related disorders can have a profound impact on the mental health and quality of life of affected individuals. Understanding the neural circuits and molecular mechanisms that trigger anxiety can aid in the development of effective targeted pharmacological treatments. Delta opioid receptors (DOP), which localize in the regions of the brain associated with emotional regulation, play a key role in the development of anxiety. Several studies have demonstrated the therapeutic effects of DOP agonists (synthetic compounds which selectively bind to DOPs and mimic the effect of the natural binding compound) in a wide range of behavioral disorders. One such selective DOP agonist -- KNT-127 -- has been shown to exert 'anxiolytic' or anxiety-reducing effects in animal models, with minimal side effects. However, its mechanism of action is not clearly understood, thereby limiting its widespread clinical application. To bridge this gap, Professor Akiyoshi Saitoh, along with Ms. Ayako Kawaminami and team from the Tokyo University of Science, Japan, conducted a series of experiments and behavioral studies in mice. Explaining the rationale behind their work, Prof. Saitoh says, "There are currently no therapeutic drugs mediated by delta opioid receptors (DOPs). DOPs likely exert anti-depressant and anti-anxiety effects through a mechanism of action different from that of existing psychotropic drugs. DOP agonists may, therefore, be useful for treatment-resistant and intractable mental illnesses which do not respond to existing treatments." Their study was published on 29 December 2023, in Neuropsychopharmacology Reports. The neuronal network projecting from the 'prelimbic cortex' (PL) of the brain to the 'basolateral nucleus of the amygdala' (BLA) region, has been implicated in the development of depression and anxiety-like symptoms. The research team has previously shown that KNT-127 inhibits the release of glutamate (a key neurotransmitter) in the PL region. Based on this, they hypothesized that DOP activation by KNT-127 suppresses glutamatergic transmission and attenuates PL-BLA-mediated anxiety-like behavior. To test this hypothesis, they developed an 'optogenetic' mouse model wherein they implanted a light-responsive chip in the PL-BLA region of mice and activated the neural circuit using light stimulation. Further, they went on to assess the role of PL-BLA activation on innate and conditioned anxiety-like behavior. They used the elevated-plus maze (EPM) test, which consists of two open arms and two closed arms on opposite sides of a central open field, to assess behavioral anxiety in the mice. Notably, mice with PL-BLA activation spent lesser time in the central region and open arms of the maze, compared to controls, which was consistent with innate anxiety-like behavior. Next, the researchers assessed conditioned fear response of the animals by exposing them to foot shocks and placing them in the same shock chamber the following day without re-exposing them to current. They recorded the freezing response of the animals which reflects fear. Notably, animals with PL-BLA activation and controls exhibited similar behavior, suggesting that distinct neural pathways control innate anxiety-like behavior and conditioned fear response. Finally, they examined the effects or KNT-127 treatment on anxiety-like behavior of mice using the EPM test. Remarkably, animals treated with KNT-127 exhibited an increase in the percentage time spent in the open arms and central field of the maze, compared to controls. These findings suggest that KNT-27 reduces anxiety-like behavior induced by the specific activation of the PL-BLA pathway. Overall, the study reveals the role of the PL-BLA neuronal axis in the regulation of innate anxiety, and its potential function in DOP-mediated anxiolytic effects. Further studies are needed to understand the precise underlying molecular and neuronal mechanisms, for the development of novel therapies targeting DOP in the PL-BLA pathway. Highlighting the long-term clinical applications of their work, Prof. Saitoh remarks, "The brain neural circuits focused on in this study are conserved in humans, and research on human brain imaging has revealed that the PL-BLA region is overactive in patients with depression and anxiety disorders. We are optimistic that suppressing overactivity in this brain region using DOP-targeted therapies can exert significant anxiolytic effects in humans."

23 Apr 2021

·www.biospace.com

Novadoz Has a Fast Start to 2021 with Generic Launches of Albendazole, Droxidopa, Deferasirox Granules, and Pregabalin ER

PISCATAWAY, N.J., April 23, 2021 /PRNewswire/ -- MSN Labs, based in Hyderabad, India, received FDA approval to market their generic versions of Albendazole 200mg tablets (AB rated to Albenza©), Droxidopa 100mg, 200mg, 300mg capsules (AB rated to Northera ©), Deferasirox Granules 180mg, 360mg sachets (AB rated to Jadenu Sprinkles©) and Pregabalin ER 82.5mg, 165mg, 330mg tablets, (AB rated to Lyrica CR©) under the Novadoz label. Novadoz is the U.S sales and marketing affiliate for MSN's portfolio of finished dosage forms. The company has commenced shipping of all the products which received approvals during Q1 2021. Albendazole 200mg is marketed in bottles of 2 tablets. It is indicated for the treatment of neurocysticercosis which is an infection caused by the pork tapeworm in the muscles, brain, and eyes that may cause seizures, brain swelling, and vision problems. The most recent 12 month published sales of the brand and generics total $26.9mil. Droxidopa 100mg, 200mg, & 300mg are available in bottles of 30 capsules. It is indicated for the symptomatic treatment of dizziness, lightheadedness, or fainting/black out sensation due to neurogenic orthostatic hypotension (a sudden fall in blood pressure). Novadoz participated in a Day 1 launch of the product, coinciding with the expiration of the brand exclusivity. Previous 12 month published sales for the brand totaled $366mil. Novadoz has also offered a patient e-voucher assistance plan for those qualified consumers needing aid to cover their out of pocket prescription co-pay costs for Droxidopa. Visit NovadozPharma.com to learn more information on the program. Among their recent FDA approvals include niche products, Deferasirox Granules 180mg, and 360mg that are available in a carton of 30 sachets. The product is used treat ongoing high levels of iron in the body caused by multiple blood transfusions. It is also used to treat high levels of iron in people with a certain blood disorder who do not require blood transfusions. The other niche offering includes Pregabalin ER 82.5mg, 165mg, and 330mg tablets available in bottles of 30. The product is indicated for the treatment of pain caused by nerve damage due to diabetes or shingles (herpes zoster). Seshu Akula, Novadoz President North America Generics, states, "The first quarter of 2021 was a very active period for the MSN/Novadoz organization with four FDA approvals. We successfully introduced these products to the market, while keeping pace with the high demand for our existing product line created by the pandemic." He adds, "MSN's position as a global leader in APIs has provided Novadoz with the scale and leveraged strength comparable to some of the largest generic pharma companies in the U.S. We are well positioned in the generic industry with a deep pipeline of oral solids, injectable, and specialty products that we expect to launch over the next 10 years." MSN Labs is engaged in the development and manufacturing of API (active pharmaceutical ingredients), KSMs (key starting materials), and product intermediates. MSN is a global leader in this category. Additionally, the company also manufactures oral solids, liquids, and specialty injectable products in sixty-five markets throughout the world, doing business in the U.S. as Novadoz Pharmaceuticals. For more information, visit the company's websites at NovadozPharma.com & MSNLabs.com. CONTACT: Tom DeStefano Novadoz Pharmaceuticals Vice President Sales and Marketing (848) 200-1909

Generic Drug

100 Deals associated with Droxidopa

External Link

KEGG	Wiki	ATC	Drug Bank
D01277	Droxidopa	C01CA27	DB06262

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetic Neuropathies	US	Lundbeck NA Ltd.	18 Feb 2014
Dizziness	US	Lundbeck NA Ltd.	18 Feb 2014
Dopamine Beta Hydroxylase Deficiency	US	Lundbeck NA Ltd.	18 Feb 2014
Hypotension, Orthostatic	JP	Sumitomo Pharma Co., Ltd.	03 Jul 2000
Amyloid Neuropathies, Familial	JP	Sumitomo Pharma Co., Ltd.	17 Jan 1989
Parkinson Disease	JP	Sumitomo Pharma Co., Ltd.	17 Jan 1989
Shy-Drager Syndrome	JP	Sumitomo Pharma Co., Ltd.	17 Jan 1989

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dopamine Beta Hydroxylase Deficiency	Phase 1	CA	Chelsea Therapeutics, Inc.	01 Jan 2008
Dopamine Beta Hydroxylase Deficiency	Phase 1	NZ	Chelsea Therapeutics, Inc.	01 Jan 2008
Dopamine Beta Hydroxylase Deficiency	Phase 1	AU	Chelsea Therapeutics, Inc.	01 Jan 2008
Hypotension orthostatic symptomatic	Phase 1	NZ	Chelsea Therapeutics, Inc.	01 Jan 2008
Hypotension orthostatic symptomatic	Phase 1	CA	Chelsea Therapeutics, Inc.	01 Jan 2008
Hypotension orthostatic symptomatic	Phase 1	US	Chelsea Therapeutics, Inc.	01 Jan 2008
Hypotension orthostatic symptomatic	Phase 1	AU	Chelsea Therapeutics, Inc.	01 Jan 2008
Pure Autonomic Failure	Phase 1	NZ	Chelsea Therapeutics, Inc.	01 Jan 2008
Pure Autonomic Failure	Discovery	US	Chelsea Therapeutics, Inc.	01 Jan 2008
Pure Autonomic Failure	Discovery	NZ	Chelsea Therapeutics, Inc.	01 Jan 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00983814 (ADD201, CTgov)	Phase 2	Attention Deficit Disorder With Hyperactivity	20	Carbidopa+Droxidopa (Droxidopa+Carbidopa: Double-Blind)	acpazkmspy(phcuonlzfb) = ngsegzaoxt huxenfprco (yqsmrdpfuj, bwdyphhvfj - eiuhmmdiob) View more	-	18 Apr 2024
				placebo+carbidopa+droxidopa (Placebo: Double-Blind)	acpazkmspy(phcuonlzfb) = qtetprhbgm huxenfprco (yqsmrdpfuj, yfgvqckcrl - nvzsvghqcu) View more
NCT02586623 (RESTORE, CTgov)	Phase 4	Neurogenic Orthostatic Hypotension \| Orthostatic hypertension	453	Droxidopa (Double-Blind Droxidopa)	ibqjzooihq(rkusrehczy) = aldgwyvyrt mfptpsirzc (glaxirqnhp, ixnbqmwnsa - ctyxtnxtwe) View more	-	23 Aug 2023
				placebo+droxidopa (Double-Blind Placebo)	ibqjzooihq(rkusrehczy) = yyiwmalggl mfptpsirzc (glaxirqnhp, edbsstuxtk - jhsnbkzeiu) View more
NCT04510922 (CTgov)	Phase 4	Hypotension, Orthostatic \| Parkinson Disease	9	Droxidopa 100 MG [Northera]	xwocbakqzj(uzirfyfxxm) = jabxvybwgb dhhkxrdjkb (jlpfougpai, rqebleajbo - pwkniuomjj) View more	-	26 Sep 2022
NCT00581477 (CTgov)	Phase 2/3	Dopamine Beta Hydroxylase Deficiency \| Hypotension, Orthostatic	8	Droxidopa (Droxidopa 25 mg)	vebdtfumdo(zafutkisfv) = pnfsfkdgpt vdudcfnkhq (rwznscbnli, txzloenotz - yqfqrmpdav) View more	-	02 Mar 2022
				Droxidopa (Droxidopa 50 mg)	vebdtfumdo(zafutkisfv) = jnajzlhjvm vdudcfnkhq (rwznscbnli, fftukvnlrc - wesqayxjbn) View more
NCT02586623 (Pubmed \| Neurol Ther)	Phase 4	Neurogenic Orthostatic Hypotension	114	Droxidopa	hlsncnuehq(jtngaffqgn) = 9% ngdljbvfyj (xjimodzant ) View more	Positive	02 Feb 2022
354 (AAN2020)	Not Applicable	Neurogenic Orthostatic Hypotension	-	Droxidopa	eprezfsgdi(mjkhheexia) = uoxhfxdmeo iipbapfuow (ewxkiakjnx )	Positive	14 Apr 2020
NCT03115827 (CTgov)	Phase 4	Parkinson Disease	15	Carbidopa+Droxidopa	bxbmjqbhgf(euvvggrgkd) = bfzcinnkhb fvomzyroge (mssprteaia, rsxzqbzryf - zznbunmmtk) View more	-	27 Jan 2020
AAN2019	Not Applicable	Neurogenic Orthostatic Hypotension	179	Droxidopa	oqbixiskzc(djtgbwtvig) = hnwlwnrfev wetlilpaye (rpwewfveqr )	-	09 Apr 2019
P3.6-047 (AAN2019)	Not Applicable	Hypotension, Orthostatic	-	Droxidopa	hfhslgsvsq(wapykpwwxd) = keedmjnmab fcvepmbubd (ivjxbxyhby, 210 - 299)	Positive	09 Apr 2019
				Midodrine	hfhslgsvsq(wapykpwwxd) = ruaaldjzdh fcvepmbubd (ivjxbxyhby, 160 - 183)
MDS2018	Not Applicable	Hypotension, Orthostatic	-	Droxidopa	nkguenhcqk(yotwbafzpy) = taooknqigw afhgkelcpy (lxgxyesipl, 210 - 299)	-	05 Oct 2018
				Midodrine	nkguenhcqk(yotwbafzpy) = gazpwguohp afhgkelcpy (lxgxyesipl, 160 - 183)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis